Status:
COMPLETED
Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain
Lead Sponsor:
AstraZeneca
Conditions:
Severe Eosinophilic Asthma
Eligibility:
All Genders
Brief Summary
Observational, retrospective study in adults (≥18 years) with severe asthma (maintenance treatment with high dose inhaled corticosteroids combined with long-acting agonist β2) and eosinophilic phenoty...
Eligibility Criteria
Inclusion
- Adult patients (age ≥18 years)
- Diagnosis of severe eosinophilic asthma requiring stable treatment of high doses of inhaled corticosteroids and a long-acting agonist β2 ± additional asthma controller
- Received at least one dose of benralizumab during the individualized access program period (March-December of 2018)
- Informed consent signed
Exclusion
- Patients enrolled in a clinical trial who received benralizumab during the same period of the individualized access program
- Refuse to sign the informed consent
Key Trial Info
Start Date :
January 13 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 8 2020
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04126499
Start Date
January 13 2020
End Date
May 8 2020
Last Update
June 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BIG PAC
Madrid, Spain